Full Press Release Details
The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway.
BIIB
The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Key Takeaway: The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Price reaction · baseline $210.63 (2022-07-01 close) · hit after-hours · clean, no other BIIB news in the window
day 0 close · peak
+0.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis